查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790427

抗生素市场规模、份额和趋势分析报告：按药物类别、类型、作用机制、地区和细分市场预测，2025 年至 2033 年

Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Fluoroquinolone), By Type (Branded Antibiotics, Generic Antibiotics), By Action Mechanism, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

抗生素市场概况

预计 2024 年全球抗生素市场规模为 530.7 亿美元，到 2033 年将达到 740.7 亿美元，2025 年至 2033 年的复合年增长率为 3.71%。抗生素市场受细菌感染疾病的流行驱动。

肺炎和支气管炎等呼吸道感染疾病(RTI) 是最常见的感染疾病之一。例如，CDC 在 2025 年 5 月估计，根据 2024 年至 2025 年的数据，美国将出现 4,700 万至 8,200 万例流感病例、2,100 万人次就诊和 64 万人次住院治疗。这些透过每週流感监测和数学建模得出的快报估计数反映了本季的疾病负担，这通常会导致需要抗生素治疗的继发性细菌感染疾病。根据 BMC Infectious Diseases 通报，尿道感染(UTI) 每年在全球造成超过 1.5 亿例，是使用抗生素的主要原因。皮肤和软组织感染疾病(SSTI)，如蜂窝组织炎，也很重要，尤其是在门诊环境中。院内感染 (HAI)，例如艰难困难梭状芽孢桿菌和抗药性金黄色葡萄球菌(MRSA)，进一步增加了需求。这些感染疾病的驱动因素包括都市化、人口老化以及不断上升的抗生素抗药性 (AMR)，这降低了现有治疗方法的有效性。在医疗保健资源有限的市场中，高感染率进一步增加了对抗生素的需求，儘管存在抗药性的挑战，但仍支撑着市场的成长。

由于高成本、盈利低，抗生素研发 (R&D) 充满挑战。开发新型抗生素成本高昂，临床试验和监管要求使成本进一步增加，而较短的治疗时间限制了收益。不过，针对多重抗药性肠道细菌的新型抗生素研发正在取得进展，重点是复杂的尿道感染。 CARB-X 于 2025 年 4 月向 ArrePath 支付 370 万美元。 ArrePath 的人工智慧平台将识别具有独特作用机制的抑制剂，可能提供口服和静脉治疗选择，以有效对抗抗菌素抗药性。例如，辉瑞于 2023 年与艾伯维合作开发新型抗生素组合，并分担成本和风险。全球 AMR 研发中心也正在协调国际努力，以加强抗生素研发管线。儘管采取了这些措施，但挑战依然存在，包括抗药性细菌的迅速出现和新药的保质期短。持续的公私合作对于克服这些障碍和确保开发有效的抗生素来对抗抗药性细菌的出现至关重要。

抗生素市场的主要企业正在采用合併、合作和技术创新等策略来保持竞争力。 2025 年 2 月，诺华以高达 21.5 亿美元（包括 9.25 亿美元的预付款）收购了中风预防项目 Anthos Therapeutics；礼来收购了 Organovo 用于治疗炎症性肠病的 FXR 项目（具体金额未披露）；Almis 以 7.37 亿美元现金与免疫介导的免疫介导公司。 2023 年，默克与 Exscientia 合作，投资超过 6.74 亿美元，将人工智慧应用于药物开发、生产和监管流程。此外，默克也与 BenevolentAI 合作，投资数亿美元用于人工智慧药物发现平台。规模较小的公司，例如 Entasis Therapeutics，其肺炎治疗药物 Xacduro 于 2023 年获得 FDA核准，则瞄准利基市场。像葛兰素史克这样的公司也在推广抗生素管理，鼓励负责任的使用。然而，学名药的竞争以及在抗药性压力下不断创新的需求，给盈利带来了挑战。这些市场发展反映出一个充满活力的市场，企业正在平衡成本管理和对新型抗生素的追求，以保持优势。

目录

第一章调查方法与范围

第二章执行摘要

第三章抗生素市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 抗生素市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析

第四章：抗生素市场（按药物类别、估计和趋势分析）

  • 2024 年及 2033 年药品类别市场占有率
  • 细分仪表板
  • 全球抗生素市场：药物类别展望
  • 2021年至2033年市场规模、预测与趋势分析
    • 头孢菌素类
    • 青霉素
    • Fluoroquinolones
    • 大环内酯类
    • 卡巴培南类
    • Aminoglycosides
    • 磺胺类药物
    • 7-ACA
    • 其他的

第五章：抗生素市场类型、预测与趋势分析

  • 2024 年及 2033 年各类型市场占有率
  • 细分仪表板
  • 全球抗生素市场：按类型展望
  • 2021年至2033年市场规模、预测与趋势分析
    • 品牌抗生素
    • 非专利药

第六章：抗生素市场的作用机制、估计与趋势分析

  • 2024年及2033年作用机制市场占有率
  • 细分仪表板
  • 全球抗生素市场：作用机制展望
  • 2021年至2033年市场规模、预测与趋势分析
    • 细胞壁合成抑制剂
    • 蛋白质合成抑制剂
    • DNA合成抑制剂
    • RNA合成抑制剂
    • 肌酸抑制剂
    • 其他的

第七章抗生素市场：区域估计/趋势分析

  • 2024 年及 2033 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2021-2033 年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 2024年主要企业市场占有率分析
    • AbbVie, Inc.
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Viatris, Inc.
    • Melinta Therapeutics LLC
    • Cipla, Inc.
    • Shionogi & Co., Ltd.
    • KYORIN Pharmaceutical Co., Ltd.
    • GSK plc
    • Nabriva Therapeutics PLC
Product Code: GVR-1-68038-149-8

Antibiotics Market Summary

The global antibiotics market size was estimated at USD 53.07 billion in 2024 and is projected to reach USD 74.07 billion by 2033, growing at a CAGR of 3.71% from 2025 to 2033, major factor contributing to market growth. The antibiotics market is driven by the prevalence of bacterial infections.

Respiratory tract infections (RTIs), such as pneumonia and bronchitis, are among the most widespread, for instance, in May 2025, the CDC estimated that the U.S. experienced between 47-82 million flu illnesses, 21 million medical visits, and 640,000 hospitalizations, based on data from 2024 - 2025. These preliminary figures, derived from weekly influenza surveillance and mathematical modeling, reflect the season's disease burden, often leading to secondary bacterial infections requiring antibiotics. Urinary tract infections (UTIs) follow closely, with over 150 million cases annually worldwide, according to BMC Infectious Diseases, making them a leading cause of antibiotic use. Skin and soft tissue infections (SSTIs), such as cellulitis, are also significant, especially in outpatient care. Hospital-acquired infections (HAIs), including Clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA), further increase demand. These infections are fueled by urbanization, aging populations, and rising antimicrobial resistance (AMR), which reduces the efficacy of existing treatments. High infection rates in developing regions with limited healthcare access further amplify the need for antibiotics, sustaining market growth despite resistance challenges.

Research and development (R&D) in antibiotics face hurdles due to high costs and low profitability. Developing new antibiotics is expensive, with clinical trials and regulatory demands adding to the burden, while short treatment durations limit returns. However, initiatives such as in April 2025, CARB-X awarded ArrePath USD 3.7 million to develop a novel antibiotic targeting multidrug-resistant Enterobacterales, focusing on complicated urinary tract infections. Using an AI-driven platform, ArrePath identified inhibitors with a unique mechanism, potentially offering oral and IV treatment options to combat antimicrobial resistance effectively. For example, Pfizer partnered with AbbVie in 2023 to develop novel antibiotic combinations, sharing costs and risks. The Global AMR R&D Hub also coordinates international efforts to bolster the antibiotic pipeline. Despite these measures, challenges persist, as resistance develops quickly, reducing the lifespan of new drugs. Sustained public-private collaboration is critical to overcoming these barriers and ensuring the development of effective antibiotics to combat rising resistance.

Key players in the antibiotics market employ strategies such as mergers, partnerships, and innovation to stay competitive. In February 2025, key biotech deals included Novartis acquiring Anthos Therapeutics for up to $2.15 billion ($925 million upfront) for its stroke prevention program, Eli Lilly buying Organovo's FXR program for inflammatory bowel disease (terms undisclosed), and the merger of Alumis and Acelyrin, focusing on immune-mediated diseases with a $737 million cash runway. In 2023, Merck invested over USD 674 million partnering with Exscientia to apply AI in drug development, manufacturing, and regulatory processes. Additionally, Merck joined forces with BenevolentAI, investing hundreds of millions more in AI drug discovery platforms. Smaller firms like Entasis Therapeutics, which gained FDA approval for Xacduro in 2023 for pneumonia, target niche markets. Companies such as GSK also promote antibiotic stewardship to encourage responsible use. However, generic competition and the need for constant innovation amid resistance pressures challenge profitability. These developments reflect a dynamic market where firms balance cost management with the pursuit of novel antibiotics to maintain their edge.

Global Antibiotics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global antibiotics market report on the basis of drug class, type, action mechanism, and region:

  • Drug Class Outlook (Revenue in USD Million, 2021 - 2033)
  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolides
  • Carbapenems
  • Aminoglycosides
  • Sulfonamides
  • 7-ACA
  • Others
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded Antibiotics
  • Generic Antibiotics
  • Action Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Action Mechanism
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class
    • 2.2.2. Type
    • 2.2.3. Action Mechanism
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antibiotics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Development of advanced products
      • 3.2.1.2. Increasing prevalence of infectious diseases
      • 3.2.1.3. Growing collaborations for development of antibiotics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High number of patent expirations
      • 3.2.2.2. High R&D cost
  • 3.3. Antibiotics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antibiotics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Antibiotics Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Cephalosporin
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Penicillin
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Fluoroquinolone
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Macrolides
      • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5. Carbapenems
      • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6. Aminoglycosides
      • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7. Sulfonamides
      • 4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8. 7-ACA
      • 4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.9. Others
      • 4.4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Antibiotics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Antibiotics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Branded Antibiotics
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Generic Antibiotics
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Antibiotics Market: Action Mechanism Estimates & Trend Analysis

  • 6.1. Action Mechanism Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Antibiotics Market by Action Mechanism Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Cell Wall Synthesis Inhibitors
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 6.4.2. Protein Synthesis Inhibitors
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. DNA Synthesis Inhibitors
      • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. RNA Synthesis Inhibitors
      • 6.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.5. Mycolic Acid Inhibitors
      • 6.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Antibiotics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. AbbVie, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Pfizer Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Novartis AG
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Merck & Co., Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Teva Pharmaceutical Industries Ltd.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Lupin Pharmaceuticals, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Viatris, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Melinta Therapeutics LLC
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Cipla, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Shionogi & Co., Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. KYORIN Pharmaceutical Co., Ltd.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. GSK plc
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
    • 8.3.16. Nabriva Therapeutics PLC
      • 8.3.16.1. Company overview
      • 8.3.16.2. Financial performance
      • 8.3.16.3. Product benchmarking
      • 8.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 4 North America Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 5 North America Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 6 U.S. Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 7 U.S. Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 8 U.S. Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 9 Canada Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 10 Canada Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 11 Canada Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 12 Mexico Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 13 Mexico Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 15 Europe Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 17 Europe Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 18 Europe Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 19 Germany Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 20 Germany Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 21 Germany Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 22 UK Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 23 UK Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 24 UK Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 25 France Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 26 France Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 27 France Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 28 Italy Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 29 Italy Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 30 Italy Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 31 Spain Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 32 Spain Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 33 Spain Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 34 Denmark Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 35 Denmark Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 36 Denmark Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 37 Sweden Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 38 Sweden Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 39 Sweden Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 40 Norway Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 41 Norway Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 42 Norway Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 47 China Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 48 China Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 49 China Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 50 Japan Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 51 Japan Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 52 Japan Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 53 India Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 54 India Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 55 India Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 56 South Korea Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 57 South Korea Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 58 South Korea Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 59 Australia Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 60 Australia Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 61 Australia Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 62 Thailand Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 63 Thailand Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 64 Thailand Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 65 Latin America Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 67 Latin America Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 68 Latin America Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 69 Brazil Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 70 Brazil Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 71 Brazil Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 72 Argentina Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 73 Argentina Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 74 Argentina Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 75 MEA Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 77 MEA Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 78 MEA Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 79 South Africa Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 80 South Africa Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 81 South Africa Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 85 UAE Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 86 UAE Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 87 UAE Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 88 Kuwait Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 89 Kuwait Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 90 Kuwait Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antibiotics market: market outlook
  • Fig. 14 Antibiotics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Antibiotics market driver impact
  • Fig. 20 Antibiotics market restraint impact
  • Fig. 21 Antibiotics market strategic initiatives analysis
  • Fig. 22 Antibiotics market: Drug Class movement analysis
  • Fig. 23 Antibiotics market: Drug Class outlook and key takeaways
  • Fig. 24 Cephalosporin market estimates and forecast, 2021 - 2033
  • Fig. 25 Penicillin market estimates and forecast, 2021 - 2033
  • Fig. 26 Fluoroquinolone market estimates and forecast, 2021 - 2033
  • Fig. 27 Macrolides market estimates and forecast, 2021 - 2033
  • Fig. 28 Carbapenems market estimates and forecast, 2021 - 2033
  • Fig. 29 Aminoglycosides market estimates and forecast, 2021 - 2033
  • Fig. 30 Sulfonamides market estimates and forecast, 2021 - 2033
  • Fig. 31 7-ACA market estimates and forecast, 2021 - 2033
  • Fig. 32 Others market estimates and forecast, 2021 - 2033
  • Fig. 33 Antibiotics Market: Type movement Analysis
  • Fig. 34 Antibiotics market: Type outlook and key takeaways
  • Fig. 35 Branded Antibiotics market estimates and forecasts, 2021 - 2033
  • Fig. 36 Generic Antibiotics market estimates and forecasts,2021 - 2033
  • Fig. 37 Antibiotics market: Action Mechanism movement analysis
  • Fig. 38 Antibiotics market: Action Mechanism outlook and key takeaways
  • Fig. 39 Cell Wall Synthesis Inhibitors market estimates and forecasts, 2021 - 2033
  • Fig. 40 Protein Synthesis Inhibitors market estimates and forecasts,2021 - 2033
  • Fig. 41 DNA Synthesis Inhibitors market estimates and forecasts,2021 - 2033
  • Fig. 42 RNA Synthesis Inhibitors market estimates and forecasts, 2021 - 2033
  • Fig. 43 Mycolic Acid Inhibitors market estimates and forecasts,2021 - 2033
  • Fig. 44 Others market estimates and forecasts, 2021 - 2033
  • Fig. 45 Global Antibiotics market: Regional movement analysis
  • Fig. 46 Global Antibiotics market: Regional outlook and key takeaways
  • Fig. 47 Global Antibiotics market share and leading players
  • Fig. 48 North America market share and leading players
  • Fig. 49 Europe market share and leading players
  • Fig. 50 Asia Pacific market share and leading players
  • Fig. 51 Latin America market share and leading players
  • Fig. 52 Middle East & Africa market share and leading players
  • Fig. 53 North America: SWOT
  • Fig. 54 Europe SWOT
  • Fig. 55 Asia Pacific SWOT
  • Fig. 56 Latin America SWOT
  • Fig. 57 MEA SWOT
  • Fig. 58 North America, by country
  • Fig. 59 North America
  • Fig. 60 North America market estimates and forecasts, 2021 - 2033
  • Fig. 61 U.S.
  • Fig. 62 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 63 Canada
  • Fig. 64 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 65 Mexico
  • Fig. 66 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 67 Europe
  • Fig. 68 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 69 UK
  • Fig. 70 UK market estimates and forecasts, 2021 - 2033
  • Fig. 71 Germany
  • Fig. 72 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 73 France
  • Fig. 74 France market estimates and forecasts, 2021 - 2033
  • Fig. 75 Italy
  • Fig. 76 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 77 Spain
  • Fig. 78 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 79 Denmark
  • Fig. 80 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 81 Sweden
  • Fig. 82 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 83 Norway
  • Fig. 84 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 85 Asia Pacific
  • Fig. 86 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 87 China
  • Fig. 88 China market estimates and forecasts, 2021 - 2033
  • Fig. 89 Japan
  • Fig. 90 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 91 India
  • Fig. 92 India market estimates and forecasts, 2021 - 2033
  • Fig. 93 Thailand
  • Fig. 94 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 95 South Korea
  • Fig. 96 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 97 Australia
  • Fig. 98 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 99 Latin America
  • Fig. 100 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 101 Brazil
  • Fig. 102 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 103 Argentina
  • Fig. 104 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 105 Rest of Latin America
  • Fig. 106 Rest of Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 107 Middle East and Africa
  • Fig. 108 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 109 South Africa
  • Fig. 110 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 111 Saudi Arabia
  • Fig. 112 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 113 UAE
  • Fig. 114 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 115 Kuwait
  • Fig. 116 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 117 Market share of key market players- Antibiotics market